Trazodone (also sold under the brand names Desyrel, Oleptro, Beneficat, Deprax,Desirel, Molipaxin, Thombran, Trazorel, Trialodine, Trittico, and Mesyrel) is anantidepressant of the serotonin antagonist and reuptake inhibitor (SARI) class. It is aphenylpiperazine compound. Trazodone also has anti-anxiety (anxiolytic) and sleep-inducing (hypnotic) effects. Trazodone has considerably fewer prominent anticholinergic(dry mouth, constipation, tachycardia) and sexual side effects than most of the tricyclic antidepressants (TCAs).
Trazodone was originally discovered and developed in Italy in the 1960s by Angelini Research Laboratories as a second-generation antidepressant. It was developed according to the mental pain hypothesis, which was postulated from studying patients and which proposes that major depression is associated with a decreased pain threshold.Trazodone was patented and marketed in many countries all over the world. It was approved by the Food and Drug Administration (FDA) at the end of 1981.
- Palazzo, G.; Silvestrini, B.; 1968, U.S. Patent 3,381,009.
- B. Silvestrini, G. Palazzo, DE 164594
- Haria M, Fitton A, McTavish D (April 1994). “Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders”. Drugs Aging 4 (4): 331–55. doi:10.2165/00002512-199404040-00006.PMID 8019056.
- ^ Silvestrini B (1989). “Trazodone: from the mental pain to the “dys-stress” hypothesis of depression”. Clin Neuropharmacol12 (Suppl 1): S4–10. doi:10.1097/00002826-198901001-00002. PMID 2568177.